Ausgabe 12/2021
Inhalt (26 Artikel)
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
Hamid Khodayari, Saeed Khodayari, Elmira Ebrahimi, Farimah Hadjilooei, Miko Vesovic, Habibollah Mahmoodzadeh, Tomo Saric, Wilfried Stücker, Stefaan Van Gool, Jürgen Hescheler, Karim Nayernia
Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity
Kirsten M. Baecher, Mandy L. Ford
Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
Inken Salewski, Steffen Kuntoff, Andreas Kuemmel, Rico Feldtmann, Stephan B. Felix, Larissa Henze, Christian Junghanss, Claudia Maletzki
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery
Michihisa Kono, Takumi Kumai, Ryusuke Hayashi, Hidekiyo Yamaki, Hiroki Komatsuda, Risa Wakisaka, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Esteban Celis, Hiroya Kobayashi, Yasuaki Harabuchi
Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism
Hui-Ming Chen, Linus Sun, Ping-Ying Pan, Lu-Hai Wang, Shu-Hsia Chen
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer
A. J. R. McGray, C. Eppolito, A. Miliotto, K. L. Singel, K. Stephenson, A. Lugade, B. H. Segal, T. Keler, G. Webster, B. Lichty, D. Kozbor, K. Odunsi
Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients
William Rodin, Patrik Sundström, Filip Ahlmanner, Louis Szeponik, Kamil Kajetan Zajt, Yvonne Wettergren, Elinor Bexe Lindskog, Marianne Quiding Järbrink
Megakaryoblastic leukemia: a study on novel role of clinically significant long non-coding RNA signatures in megakaryocyte development during treatment with phorbol ester
Swati Dahariya, Sanjeev Raghuwanshi, Anjali Sangeeth, Mahesh Malleswarapu, Ravinder Kandi, Ravi Kumar Gutti
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas
Naoki Oike, Hiroyuki Kawashima, Akira Ogose, Hiroshi Hatano, Takashi Ariizumi, Tetsuro Yamagishi, Yudai Murayama, Hajime Umezu, Chihaya Imai, Masanori Hayashi, Naoto Endo
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
Wenyi Lu, Yunxiong Wei, Yaqing Cao, Xia Xiao, Qing Li, Hairong Lyu, Yili Jiang, Huan Zhang, Xin Li, Yanyu Jiang, Juanxia Meng, Ting Yuan, Haibo Zhu, Xiaoyuan He, Xin Jin, Rui Sun, Tao Sui, Kaiqi Liu, Mingfeng Zhao
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
Xi Chen, Liangjie Fang, Yanping Zhu, Zhang Bao, Qing Wang, Rong Liu, Wenjia Sun, Haiwei Du, Jing Lin, Bing Yu, Songan Chen, Jianya Zhou, Jianying Zhou
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade
Kyle Hansen, Sandeep Kumar, Kathryn Logronio, Sarah Whelan, Samir Qurashi, Hsin-Yuan Cheng, Andrew Drake, Margaret Tang, Patrick Wall, David Bernados, Ling Leung, Eran Ophir, Zoya Alteber, Gady Cojocaru, Moran Galperin, Masha Frenkel, Mark White, John Hunter, Spencer C. Liang, Maya F. Kotturi
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
Hai-Jun Hu, Xiu Liang, Hai-Lang Li, Huai-Yuan Wang, Jin-Fa Gu, Lan-Ying Sun, Jing Xiao, Jin-Qing Hu, Ai-Min Ni, Xin-Yuan Liu
IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors
Mamoru Tasaki, Midori Yamashita, Yukinori Arai, Takafumi Nakamura, Shinsuke Nakao
Immune infiltrate diversity confers a good prognosis in follicular lymphoma
Anna-Maria Tsakiroglou, Susan Astley, Manàs Dave, Martin Fergie, Elaine Harkness, Adeline Rosenberg, Matthew Sperrin, Catharine West, Richard Byers, Kim Linton
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy
Daojun Lv, Xiangkun Wu, Xi Chen, Shuxin Yang, Wenzhe Chen, Ming Wang, Yongda Liu, Di Gu, Guohua Zeng
CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer
Pin Wu, Lufeng Zhao, Yongyuan Chen, Zhongwei Xin, Mingjie Lin, Zhixing Hao, Xiaoke Chen, Di Chen, Dang Wu, Ying Chai
Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in mice
Edgardo Berriel, Teresa Freire, Carolina Chiale, Ernesto Rodríguez, Gabriel Morón, Gabriel Fernández-Graña, Martina Crispo, Nora Berois, Eduardo Osinaga
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Karin Enell Smith, Peter Ellmark
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
Maximilian J. Mair, Ayseguel Ilhan-Mutlu, Sahra Pajenda, Barbara Kiesel, Adelheid Wöhrer, Georg Widhalm, Karin Dieckmann, Christine Marosi, Ludwig Wagner, Matthias Preusser, Anna S. Berghoff
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma
Tao Fan, Yu Liu, Hengchang Liu, Liyu Wang, He Tian, Yujia Zheng, Bo Zheng, Liyan Xue, Fengwei Tan, Qi Xue, Shungeng Gao, Chunxiang Li, Jie He
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome
Keitaro Kanie, Genzo Iguchi, Hironori Bando, Shin Urai, Hiroki Shichi, Yasunori Fujita, Ryusaku Matsumoto, Kentaro Suda, Masaaki Yamamoto, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial
Gilberto Filaci, Daniela Fenoglio, Franco Nolè, Elisa Zanardi, Laura Tomasello, Massimo Aglietta, Gianluca Del Conte, Joan Carles, Rafael Morales-Barrera, Pamela Guglielmini, Giorgio Scagliotti, Alessio Signori, Alessia Parodi, Francesca Kalli, Giuseppina Astone, Francesca Ferrera, Tiziana Altosole, Giuseppina Lamperti, Domenico Criscuolo, Francesco Gianese, Francesco Boccardo
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
Christiane Braun, Sebastian Schlaweck, Solveig Nora Daecke, Peter Brossart, Annkristin Heine
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
Sarah B. Reusing, Dan A. Vallera, Angela R. Manser, Titus Vatrin, Sanil Bhatia, Martin Felices, Jeffrey S. Miller, Markus Uhrberg, Florian Babor
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
Sarah B. Reusing, Dan A. Vallera, Angela R. Manser, Titus Watrin, Sanil Bhatia, Martin Felices, Jeffrey S. Miller, Markus Uhrberg, Florian Babor